The company Tinnitech is born
The Tinnitech company was founded by a group of technologists and doctors dedicated to creating an innovative solution to the unresolved problem of tinnitus in Italy and in the world. The founders were joined by Professor Bruno Brandimarte, a historical student of Fermi’s “Panisperna boys”, a former professor of physics and anatomy, a serial patent holder and above all an expert in “coordination between medical devices and pharmacology”. Brandimarte becomes head of research and main inventor of the project in November 2016, when our first patent is filed.
Distribution of the device in Italy
The release of the clinical results and benefits for patients in Italy begins. The dream of the founders of Tinnitech to treat the many Italians suffering from tinnitus with this innovative and particularly promising therapy comes true.
Clinical and Technological results
The Technology is consolidated with additional IT capabilities, multi-frequency, basic tinnitus, advanced mobility and telemedicine.
The two patents are granted on an international scale and for all three parameters of intellectual property and industrial invention.
In June, the Tor Vergata Hospital protocol T0001/22 is completed. The results are very promising and are disseminated to the SIO (national ENT congress) and in the Press.
From September 2023, work has been carried out on the transformation of the “Acufree prototype” into the first anti-tinnitus serial production with “synchronized multimodal
methodology”.
In October 2023 well-known Prof. Burioni published a famous book on multiple therapies for incurable diseases, as happy coincidence with the dissemination in the national media of our success with our own, unique tinnitus “multimodal therapy” (i.e. simultaneous aggression of the diseases).
In November, the positive results of Tor Vergata protocol T0001/22 are made official after 12 months,, that is: tinnitus relief that lasts! The 1-year improvements are presented at the SIAF – national congress of audiology, speaker Prof. Di Girolamo, ENT Director of Tor Vergata and scientific director of the clinical study.